RGNX

RGNX R&D to Revenue

133.95%Fiscal year

Period ending:

RGNX FY R&D/Revenue%
RGNX FY R&D/Revenue1105.44%-75.94%
2013-12-312025-12-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods. Dates are period ends; a fiscal year may differ from a calendar year.

RGNX r&d to revenue history

R&D spending as percentage of revenue. The available annual fiscal periods series contains 13 observations from Dec 31, 2013 to Dec 31, 2025.

Regenxbio Inc R&D to Revenue — Annual fiscal periods
Period endingR&D to Revenue
133.9461%
250.2424%
257.3813%
215.0855%
38.5751%
107.587%
352.4679%
38.3849%
550.6014%
991.1092%
227.7148%
81.0621%
82.9801%

Compare r&d to revenue

All RGNX financial metrics · RGNX stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.